About HealthLinx Limited (ASX:HTX)
-----------------------------------
HealthLinx uses biomarkers to develop best practice diagnostics that detect and monitor diseases. First commercial targets are for diseases with high fatality:
?
Ovarian cancer diagnostic (OvPlex) targeting US$270m pa market
?
Prostate cancer targeting US$350m pa market
Current Scenario
----------------
Larger OvPlex? study confirms 93% diagnostic efficiency for ovarian cancer
Shares Outstanding : 148M
Is this .065c not very cheap?
About HealthLinx Limited...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
